Ziad Hijazi

Biomarker-Based Model for Prediction of Ischemic Stroke in Patients With Atrial Fibrillation

Wallentin, Lars; Lindbäck, Johan; Hijazi, Ziad; Oldgren, Jonas et al.

Ingår i Journal of the American College of Cardiology, 2025

• DOI för Biomarker-Based Model for Prediction of Ischemic Stroke in Patients With Atrial Fibrillation

Randomized Invitation to Systematic NT-proBNP and ECG Screening in 75-Year-Olds to Detect Atrial Fibrillation: STROKESTOP II

Kemp Gudmundsdottir, Katrin; Svennberg, Emma; Friberg, Leif; Hygrell, Tove et al.

Ingår i Circulation, s. 1837-1846, 2024

• DOI för Randomized Invitation to Systematic NT-proBNP and ECG Screening in 75-Year-Olds to Detect Atrial Fibrillation: STROKESTOP II

Heart Failure Risk Assessment Using Biomarkers in Patients With Atrial Fibrillation: Analysis From COMBINE-AF

Haller, Paul M.; Jarolim, Petr; Palazzolo, Michael G.; Bellavia, Andrea et al.

Ingår i Journal of the American College of Cardiology, s. 1528-1540, 2024

• DOI för Heart Failure Risk Assessment Using Biomarkers in Patients With Atrial Fibrillation: Analysis From COMBINE-AF

Repeated Measurement of the Novel Atrial Biomarker BMP10 (Bone Morphogenetic Protein 10) Refines Risk Stratification in Anticoagulated Patients With Atrial Fibrillation: Insights From the ARISTOTLE Trial

Gkarmiris, Konstantinos I.; Lindbäck, Johan; Alexander, John H.; Granger, Christopher B. et al.

Ingår i Journal of the American Heart Association, 2024

• DOI för Repeated Measurement of the Novel Atrial Biomarker BMP10 (Bone Morphogenetic Protein 10) Refines Risk Stratification in Anticoagulated Patients With Atrial Fibrillation: Insights From the ARISTOTLE Trial
• Ladda ner fulltext (pdf) av Repeated Measurement of the Novel Atrial Biomarker BMP10 (Bone Morphogenetic Protein 10) Refines Risk Stratification in Anticoagulated Patients With Atrial Fibrillation: Insights From the ARISTOTLE Trial

Longer and better lives for patients with atrial fibrillation: the 9th AFNET/EHRA consensus conference

Linz, Dominik; Andrade, Jason G.; Arbelo, Elena; Boriani, Giuseppe et al.

Ingår i Europace, 2024

• DOI för Longer and better lives for patients with atrial fibrillation: the 9th AFNET/EHRA consensus conference
• Ladda ner fulltext (pdf) av Longer and better lives for patients with atrial fibrillation: the 9th AFNET/EHRA consensus conference

Neurofilament Light Chain and Risk of Stroke in Patients With Atrial Fibrillation

Aulin, Julia; Sjölin, Karl; Lindbäck, Johan; Benz, Alexander P et al.

Ingår i Circulation, s. 1090-1100, 2024

• DOI för Neurofilament Light Chain and Risk of Stroke in Patients With Atrial Fibrillation

Data standards for atrial fibrillation/flutter and catheter ablation: The European Unified Registries for Heart Care Evaluation and Randomized Trials (EuroHeart)

Batra, Gorav; Aktaa, Suleman; Camm, A. John; Costa, Francisco et al.

Ingår i European Heart Journal - Quality of Care and Clinical Outcomes, s. 609-620, 2023

• DOI för Data standards for atrial fibrillation/flutter and catheter ablation: The European Unified Registries for Heart Care Evaluation and Randomized Trials (EuroHeart)
• Ladda ner fulltext (pdf) av Data standards for atrial fibrillation/flutter and catheter ablation: The European Unified Registries for Heart Care Evaluation and Randomized Trials (EuroHeart)

ABC-AF-Stroke score predicts thromboembolism in non-anticoagulated patients following successful atrial fibrillation ablation: a report from the Chinese Atrial Fibrillation Registry

Wang, Yufeng; Jiang, Chao; He, Liu; Du, Xin et al.

Ingår i Chinese Medical Journal, s. 2451-2458, 2023

• DOI för ABC-AF-Stroke score predicts thromboembolism in non-anticoagulated patients following successful atrial fibrillation ablation: a report from the Chinese Atrial Fibrillation Registry
• Ladda ner fulltext (pdf) av ABC-AF-Stroke score predicts thromboembolism in non-anticoagulated patients following successful atrial fibrillation ablation: a report from the Chinese Atrial Fibrillation Registry

Plasma angiopoietin-2 and its association with heart failure in patients with atrial fibrillation

Benz, Alexander P.; Hijazi, Ziad; Lindbäck, Johan; Connolly, Stuart J. et al.

Ingår i Europace, 2023

• DOI för Plasma angiopoietin-2 and its association with heart failure in patients with atrial fibrillation
• Ladda ner fulltext (pdf) av Plasma angiopoietin-2 and its association with heart failure in patients with atrial fibrillation

Direct Oral Anticoagulants Versus Warfarin Across the Spectrum of Kidney Function: Patient-Level Network Meta-Analyses From COMBINE AF

Harrington, Josephine; Carnicelli, Anthony P.; Hua, Kaiyuan; Wallentin, Lars et al.

Ingår i Circulation, s. 1748-1757, 2023

• DOI för Direct Oral Anticoagulants Versus Warfarin Across the Spectrum of Kidney Function: Patient-Level Network Meta-Analyses From COMBINE AF

Heart rate and death and hospitalization for heart failure in patients with persistent or permanent atrial fibrillation: Insights from the ARISTOTLE trial

Vinereanu, Dragos; Wojdyla, Daniel M.; Alexander, John H.; Lopes, Renato D. et al.

Ingår i American Heart Journal, s. 132-136, 2023

• DOI för Heart rate and death and hospitalization for heart failure in patients with persistent or permanent atrial fibrillation: Insights from the ARISTOTLE trial

Outcomes of patients with atrial fibrillation and ischemic stroke while on oral anticoagulation

Benz, Alexander P.; Hohnloser, Stefan H.; Eikelboom, John W.; Carnicelli, Anthony P. et al.

Ingår i European Heart Journal, s. 1807-1814, 2023

• DOI för Outcomes of patients with atrial fibrillation and ischemic stroke while on oral anticoagulation

Individual net clinical outcome with oral anticoagulation in atrial fibrillation using the ABC-AF risk scores

Hijazi, Ziad; Lindbäck, Johan; Oldgren, Jonas; Benz, Alexander P. et al.

Ingår i American Heart Journal, s. 55-63, 2023

• DOI för Individual net clinical outcome with oral anticoagulation in atrial fibrillation using the ABC-AF risk scores
• Ladda ner fulltext (pdf) av Individual net clinical outcome with oral anticoagulation in atrial fibrillation using the ABC-AF risk scores

Early Versus Delayed Non-Vitamin K Antagonist Oral Anticoagulant Therapy After Acute Ischemic Stroke in Atrial Fibrillation (TIMING): A Registry-Based Randomized Controlled Noninferiority Study

Oldgren, Jonas; Åsberg, Signild; Hijazi, Ziad; Wester, Per et al.

Ingår i Circulation, s. 1056-1066, 2022

• DOI för Early Versus Delayed Non-Vitamin K Antagonist Oral Anticoagulant Therapy After Acute Ischemic Stroke in Atrial Fibrillation (TIMING): A Registry-Based Randomized Controlled Noninferiority Study
• Ladda ner fulltext (pdf) av Early Versus Delayed Non-Vitamin K Antagonist Oral Anticoagulant Therapy After Acute Ischemic Stroke in Atrial Fibrillation (TIMING): A Registry-Based Randomized Controlled Noninferiority Study

The ABC-Stroke Score Refines Stroke Risk Stratification in Patients With Atrial Fibrillation at the Emergency Department

Niederdöckl, Jan; Oppenauer, Julia; Schnaubelt, Sebastian; Cacioppo, Filippo et al.

Ingår i Frontiers in Medicine, 2022

• DOI för The ABC-Stroke Score Refines Stroke Risk Stratification in Patients With Atrial Fibrillation at the Emergency Department
• Ladda ner fulltext (pdf) av The ABC-Stroke Score Refines Stroke Risk Stratification in Patients With Atrial Fibrillation at the Emergency Department

Bone morphogenetic protein 10: a novel risk marker of ischaemic stroke in patients with atrial fibrillation

Hijazi, Ziad; Benz, Alexander P.; Lindbäck, Johan; Alexander, John H. et al.

Ingår i European Heart Journal, s. 208-218, 2022

• DOI för Bone morphogenetic protein 10: a novel risk marker of ischaemic stroke in patients with atrial fibrillation
• Ladda ner fulltext (pdf) av Bone morphogenetic protein 10: a novel risk marker of ischaemic stroke in patients with atrial fibrillation

Association of GDF-15, hs-cTnT and NT-proBNP with coronary artery disease in patients undergoing elective angiography

Souaid, Tarek; Hijazi, Ziad; Barakett, Vanda; Sarkis, Antoine et al.

Ingår i Future Cardiology, s. 635-646, 2022

• DOI för Association of GDF-15, hs-cTnT and NT-proBNP with coronary artery disease in patients undergoing elective angiography

Duration of Anticoagulation Interruption Before Invasive Procedures and Outcomes in Patients With Atrial Fibrillation: Insights From the ARISTOTLE Trial

Al-Khatib, Sana M.; Wojdyla, Daniel M.; Granger, Christopher B.; Wallentin, Lars et al.

Ingår i Circulation, s. 958-960, 2022

• DOI för Duration of Anticoagulation Interruption Before Invasive Procedures and Outcomes in Patients With Atrial Fibrillation: Insights From the ARISTOTLE Trial

Direct Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation: Patient-Level Network Meta-Analyses of Randomized Clinical Trials With Interaction Testing by Age and Sex

Carnicelli, Anthony P.; Hong, Hwanhee; Connolly, Stuart J.; Eikelboom, John et al.

Ingår i Circulation, s. 242-255, 2022

• DOI för Direct Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation: Patient-Level Network Meta-Analyses of Randomized Clinical Trials With Interaction Testing by Age and Sex

Biomarkers and heart failure events in patients with atrial fibrillation in the ARISTOTLE trial evaluated by a multi-state model

Aulin, Julia; Hijazi, Ziad; Lindbäck, Johan; Alexander, John H. et al.

Ingår i American Heart Journal, s. 13-24, 2022

• DOI för Biomarkers and heart failure events in patients with atrial fibrillation in the ARISTOTLE trial evaluated by a multi-state model
• Ladda ner fulltext (pdf) av Biomarkers and heart failure events in patients with atrial fibrillation in the ARISTOTLE trial evaluated by a multi-state model

Risk markers of incident atrial fibrillation in patients with coronary heart disease

Tomasdottir, Maria; Held, Claes; Hadziosmanovic, Nermin; Westerbergh, Johan et al.

Ingår i American Heart Journal, s. 92-101, 2021

• DOI för Risk markers of incident atrial fibrillation in patients with coronary heart disease
• Ladda ner fulltext (pdf) av Risk markers of incident atrial fibrillation in patients with coronary heart disease

Apixaban or Vitamin K Antagonists and Aspirin or Placebo According to Kidney Function in Patients With Atrial Fibrillation After Acute Coronary Syndrome or Percutaneous Coronary Intervention: Insights From the AUGUSTUS Trial

Hijazi, Ziad; Alexander, John H.; Li, Zhuokai; Wojdyla, Daniel M. et al.

Ingår i Circulation, s. 1215-1223, 2021

• DOI för Apixaban or Vitamin K Antagonists and Aspirin or Placebo According to Kidney Function in Patients With Atrial Fibrillation After Acute Coronary Syndrome or Percutaneous Coronary Intervention: Insights From the AUGUSTUS Trial

Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Left Ventricular Hypertrophy: Insights From the ARISTOTLE Trial

Al-Khatib, Sana M.; Mulder, Hillary; Wojdyla, Daniel; Lopes, Renato D. et al.

Ingår i Circulation, s. 359-361, 2021

• DOI för Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Left Ventricular Hypertrophy: Insights From the ARISTOTLE Trial

Evaluation of the prognostic value of GDF-15, ABC-AF-bleeding score and ABC-AF-death score in patients with atrial fibrillation across different geographical areas

Pol, Tymon; Hijazi, Ziad; Lindbäck, Johan; Alexander, John H. et al.

Ingår i Open heart, 2021

• DOI för Evaluation of the prognostic value of GDF-15, ABC-AF-bleeding score and ABC-AF-death score in patients with atrial fibrillation across different geographical areas
• Ladda ner fulltext (pdf) av Evaluation of the prognostic value of GDF-15, ABC-AF-bleeding score and ABC-AF-death score in patients with atrial fibrillation across different geographical areas

Biomarker-Based Risk Prediction With the ABC-AF Scores in Patients With Atrial Fibrillation Not Receiving Oral Anticoagulation

Benz, Alexander P.; Hijazi, Ziad; Lindbäck, Johan; Connolly, Stuart J. et al.

Ingår i Circulation, s. 1863-1873, 2021

• DOI för Biomarker-Based Risk Prediction With the ABC-AF Scores in Patients With Atrial Fibrillation Not Receiving Oral Anticoagulation

Multiplex protein screening of biomarkers associated with major bleeding in patients with atrial fibrillation treated with oral anticoagulation.

Siegbahn, Agneta; Lindbäck, Johan; Hijazi, Ziad; Åberg, Mikael et al.

Ingår i Journal of Thrombosis and Haemostasis, s. 2726-2737, 2021

• DOI för Multiplex protein screening of biomarkers associated with major bleeding in patients with atrial fibrillation treated with oral anticoagulation.
• Ladda ner fulltext (pdf) av Multiplex protein screening of biomarkers associated with major bleeding in patients with atrial fibrillation treated with oral anticoagulation.

Using multimarker screening to identify biomarkers associated with cardiovascular death in patients with atrial fibrillation.

Pol, Tymon; Hijazi, Ziad; Lindbäck, Johan; Oldgren, Jonas et al.

Ingår i Cardiovascular Research, s. 2112-2123, 2021

• DOI för Using multimarker screening to identify biomarkers associated with cardiovascular death in patients with atrial fibrillation.
• Ladda ner fulltext (pdf) av Using multimarker screening to identify biomarkers associated with cardiovascular death in patients with atrial fibrillation.

Biomarker-based risk scores in atrial fibrillation

Hijazi, Ziad; Mills, Nicholas L; Mueller, Christian

Ingår i European Heart Journal, s. 1084-1085, 2021

• DOI för Biomarker-based risk scores in atrial fibrillation

Natriuretic peptides and incident atrial fibrillation

Tomasdottir, Maria; Held, Claes; Wallentin, Lars; Hijazi, Ziad

Ingår i American Heart Journal, s. 1-1, 2021

• DOI för Natriuretic peptides and incident atrial fibrillation

Cardiac troponin is associated with cardiac outcomes in men and women with atrial fibrillation, insights from the ARISTOTLE trial

Rosjo, H.; Hijazi, Ziad; Omland, T.; Westerbergh, Johan et al.

Ingår i Journal of Internal Medicine, s. 248-259, 2020

• DOI för Cardiac troponin is associated with cardiac outcomes in men and women with atrial fibrillation, insights from the ARISTOTLE trial
• Ladda ner fulltext (pdf) av Cardiac troponin is associated with cardiac outcomes in men and women with atrial fibrillation, insights from the ARISTOTLE trial

Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Advanced Chronic Kidney Disease

Stanifer, John W.; Pokorney, Sean D.; Chertow, Glenn M.; Hohnloser, Stefan H. et al.

Ingår i Circulation, s. 1384-1392, 2020

• DOI för Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Advanced Chronic Kidney Disease

Angiotensin-converting enzyme 2 (ACE2) levels in relation to risk factors for COVID-19 in two large cohorts of patients with atrial fibrillation.

Wallentin, Lars; Lindbäck, Johan; Eriksson, Niclas; Hijazi, Ziad et al.

Ingår i European Heart Journal, s. 4037-4046, 2020

• DOI för Angiotensin-converting enzyme 2 (ACE2) levels in relation to risk factors for COVID-19 in two large cohorts of patients with atrial fibrillation.

Serial measurement of interleukin-6 and risk of mortality in anticoagulated patients with atrial fibrillation: Insights from ARISTOTLE and RE-LY trials.

Aulin, Julia; Hijazi, Ziad; Siegbahn, Agneta; Andersson, Ulrika et al.

Ingår i Journal of Thrombosis and Haemostasis, s. 2287-2295, 2020

• DOI för Serial measurement of interleukin-6 and risk of mortality in anticoagulated patients with atrial fibrillation: Insights from ARISTOTLE and RE-LY trials.
• Ladda ner fulltext (pdf) av Serial measurement of interleukin-6 and risk of mortality in anticoagulated patients with atrial fibrillation: Insights from ARISTOTLE and RE-LY trials.

Screening of Multiple Biomarkers Associated With Ischemic Stroke in Atrial Fibrillation

Hijazi, Ziad; Wallentin, Lars; Lindbäck, Johan; Alexander, John H. et al.

Ingår i Journal of the American Heart Association, 2020

• DOI för Screening of Multiple Biomarkers Associated With Ischemic Stroke in Atrial Fibrillation
• Ladda ner fulltext (pdf) av Screening of Multiple Biomarkers Associated With Ischemic Stroke in Atrial Fibrillation

Evaluation of the Age, Biomarkers, and Clinical History-Bleeding Risk Score in Patients With Atrial Fibrillation With Combined Aspirin and Anticoagulation Therapy Enrolled in the ARISTOTLE and RE-LY Trials

Hijazi, Ziad; Oldgren, Jonas; Lindbäck, Johan; Alexander, John H. et al.

Ingår i JAMA Network Open, 2020

• DOI för Evaluation of the Age, Biomarkers, and Clinical History-Bleeding Risk Score in Patients With Atrial Fibrillation With Combined Aspirin and Anticoagulation Therapy Enrolled in the ARISTOTLE and RE-LY Trials

Regional variation in clinical characteristics and outcomes in patients with atrial fibrillation: Findings from the ARISTOTLE trial

Bahit, M. Cecilia; Granger, Christopher B.; Alexander, John H.; Mulder, Hillary et al.

Ingår i International Journal of Cardiology, s. 53-58, 2020

• DOI för Regional variation in clinical characteristics and outcomes in patients with atrial fibrillation: Findings from the ARISTOTLE trial

Cardiovascular outcomes, bleeding risk, and achieved blood pressure in patients on long-term anticoagulation with the thrombin antagonist dabigatran or warfarin: data from the RE-LY trial

Böhm, Michael; Brueckmann, Martina; Eikelboom, John W.; Ezekowitz, Michael et al.

Ingår i European Heart Journal, s. 2848-2859, 2020

• DOI för Cardiovascular outcomes, bleeding risk, and achieved blood pressure in patients on long-term anticoagulation with the thrombin antagonist dabigatran or warfarin: data from the RE-LY trial

Stepwise mass screening for atrial fibrillation using N-terminal B-type natriuretic peptide: the STROKESTOP II study

Gudmundsdottir, Katrin Kemp; Fredriksson, Tove; Svennberg, Emma; Al-Khalili, Faris et al.

Ingår i Europace, s. 24-32, 2020

• DOI för Stepwise mass screening for atrial fibrillation using N-terminal B-type natriuretic peptide: the STROKESTOP II study
• Ladda ner fulltext (pdf) av Stepwise mass screening for atrial fibrillation using N-terminal B-type natriuretic peptide: the STROKESTOP II study

Association of Different Estimates of Renal Function With Cardiovascular Mortality and Bleeding in Atrial Fibrillation

Hijazi, Ziad; Granger, Christopher B.; Hohnloser, Stefan H.; Westerbergh, Johan et al.

Ingår i Journal of the American Heart Association, 2020

• DOI för Association of Different Estimates of Renal Function With Cardiovascular Mortality and Bleeding in Atrial Fibrillation

Risk of ischemic stroke and utility of CHA₂DS₂-VASc score in women and men with atrial fibrillation

Tomasdottir, Maria; Friberg, Leif; Hijazi, Ziad; Lindbäck, Johan et al.

Ingår i Clinical Cardiology, s. 1003-1009, 2019

• DOI för Risk of ischemic stroke and utility of CHA₂DS₂-VASc score in women and men with atrial fibrillation
• Ladda ner fulltext (pdf) av Risk of ischemic stroke and utility of CHA₂DS₂-VASc score in women and men with atrial fibrillation

International normalized ratio control and subsequent clinical outcomes in patients with atrial fibrillation using warfarin

Guimaraes, Patricia O.; Lopes, Renato D.; Alexander, John H.; Thomas, Laine et al.

Ingår i Journal of Thrombosis and Thrombolysis, s. 27-34, 2019

• DOI för International normalized ratio control and subsequent clinical outcomes in patients with atrial fibrillation using warfarin

Natriuretic peptide should be used as a routine tool for evaluation of patients with atrial fibrillation

Hijazi, Ziad; Wallentin, Lars

Ingår i Heart, s. 353-354, 2019

• DOI för Natriuretic peptide should be used as a routine tool for evaluation of patients with atrial fibrillation

Outcomes of apixaban versus warfarin in patients with atrial fibrillation and multi-morbidity: Insights from the ARISTOTLE trial

Alexander, Karen P; Brouwer, Marc A; Mulder, Hillary; Vinereanu, Dragos et al.

Ingår i American Heart Journal, s. 123-131, 2019

• DOI för Outcomes of apixaban versus warfarin in patients with atrial fibrillation and multi-morbidity: Insights from the ARISTOTLE trial

Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation

Lopes, Renato D.; Heizer, Gretchen; Aronson, Ronald; Vora, Amit N. et al.

Ingår i New England Journal of Medicine, s. 1509-1524, 2019

• DOI för Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation

Efficacy and Safety of Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Extremes in Body Weight: Insights From the ARISTOTLE Trial

Hohnloser, Stefan H.; Fudim, Marat; Alexander, John H.; Wojdyla, Daniel M. et al.

Ingår i Circulation, s. 2292-2300, 2019

• DOI för Efficacy and Safety of Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Extremes in Body Weight: Insights From the ARISTOTLE Trial

Cardiac Biomarkers and Left Ventricular Hypertrophy in Relation to Outcomes in Patients With Atrial Fibrillation: Experiences From the RE-LY Trial

Hijazi, Ziad; Verdecchia, Paolo; Oldgren, Jonas; Andersson, Ulrika et al.

Ingår i Journal of the American Heart Association, 2019

• DOI för Cardiac Biomarkers and Left Ventricular Hypertrophy in Relation to Outcomes in Patients With Atrial Fibrillation: Experiences From the RE-LY Trial
• Ladda ner fulltext (pdf) av Cardiac Biomarkers and Left Ventricular Hypertrophy in Relation to Outcomes in Patients With Atrial Fibrillation: Experiences From the RE-LY Trial

Obesity paradox on outcome in atrial fibrillation maintained even considering the prognostic influence of biomarkers: insights from the ARISTOTLE trial

Sandhu, Roopinder K.; Ezekowitz, Justin A.; Hijazi, Ziad; Westerbergh, Johan et al.

Ingår i Open heart, 2018

• DOI för Obesity paradox on outcome in atrial fibrillation maintained even considering the prognostic influence of biomarkers: insights from the ARISTOTLE trial
• Ladda ner fulltext (pdf) av Obesity paradox on outcome in atrial fibrillation maintained even considering the prognostic influence of biomarkers: insights from the ARISTOTLE trial

Use of Biomarkers to Predict Specific Causes of Death in Patients With Atrial Fibrillation: Insights From the ARISTOTLE Trial

Sharma, Abhinav; Hijazi, Ziad; Andersson, Ulrika; Al-Khatib, Sana M. et al.

Ingår i Circulation, s. 1666-1676, 2018

• DOI för Use of Biomarkers to Predict Specific Causes of Death in Patients With Atrial Fibrillation: Insights From the ARISTOTLE Trial

A biomarker-based risk score to predict death in patients with atrial fibrillation: the ABC (age, biomarkers, clinical history) death risk score

Hijazi, Ziad; Oldgren, Jonas; Lindbäck, Johan; Alexander, John H. et al.

Ingår i European Heart Journal, s. 477-485, 2018

• DOI för A biomarker-based risk score to predict death in patients with atrial fibrillation: the ABC (age, biomarkers, clinical history) death risk score
• Ladda ner fulltext (pdf) av A biomarker-based risk score to predict death in patients with atrial fibrillation: the ABC (age, biomarkers, clinical history) death risk score

New Biomarkers Associated With Cardiovascular Death In Patients With Atrial Fibrillation Using Multimarker Screening: Insights From The Aristotle Trial

Pol, Tymon; Hijazi, Ziad; Lindbäck, Johan; Oldgren, Jonas et al.

Ingår i Journal of the American College of Cardiology, s. 330-330, 2018

• DOI för New Biomarkers Associated With Cardiovascular Death In Patients With Atrial Fibrillation Using Multimarker Screening: Insights From The Aristotle Trial

Novel Prognostic Biomarkers For Ischemic Stroke In Patients With Atrial Fibrillation Using Multimarker Screening: Insights From The Aristotle Trial

Hijazi, Ziad; Pol, Tymon; Oldgren, Jonas; Lindbäck, Johan et al.

Ingår i Journal of the American College of Cardiology, s. 506-506, 2018

Efficacy and safety of dabigatran compared with warfarin in patients with atrial fibrillation in relation to renal function over time-A RE-LY trial analysis

Hijazi, Ziad; Hohnloser, Stefan H.; Oldgren, Jonas; Andersson, Ulrika et al.

Ingår i American Heart Journal, s. 169-177, 2018

• DOI för Efficacy and safety of dabigatran compared with warfarin in patients with atrial fibrillation in relation to renal function over time-A RE-LY trial analysis

Dyslipidemia and Risk of Cardiovascular Events in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Therapy: Insights From the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) Trial

Pol, Tymon; Held, Claes; Westerbergh, Johan; Lindbäck, Johan et al.

Ingår i Journal of the American Heart Association, 2018

• DOI för Dyslipidemia and Risk of Cardiovascular Events in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Therapy: Insights From the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) Trial

The Science of Prognosis in Psychiatry: A Review

Fusar-Poli, Paolo; Hijazi, Ziad; Stahl, Daniel; Steyerberg, Ewout W.

Ingår i JAMA psychiatry, s. 1289-1297, 2018

• DOI för The Science of Prognosis in Psychiatry: A Review

Comparison of bleeding risk scores in patients with atrial fibrillation: insights from the RE-LY trial

Proietti, M.; Hijazi, Ziad; Andersson, Ulrika; Connolly, S. J. et al.

Ingår i Journal of Internal Medicine, s. 282-292, 2018

• DOI för Comparison of bleeding risk scores in patients with atrial fibrillation: insights from the RE-LY trial

Growth-differentiation factor 15 and risk of major bleeding in atrial fibrillation: Insights from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial

Hijazi, Ziad; Oldgren, Jonas; Andersson, Ulrika; Connolly, Stuart J et al.

Ingår i American Heart Journal, s. 94-103, 2017

• DOI för Growth-differentiation factor 15 and risk of major bleeding in atrial fibrillation: Insights from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial

Timing of oral anticoagulant therapy in acute ischemic stroke with atrial fibrillation: study protocol for a registry-based randomised controlled trial

Åsberg, Signild; Hijazi, Ziad; Norrving, Bo; Terént, Andreas et al.

Ingår i Trials, 2017

• DOI för Timing of oral anticoagulant therapy in acute ischemic stroke with atrial fibrillation: study protocol for a registry-based randomised controlled trial
• Ladda ner fulltext (pdf) av Timing of oral anticoagulant therapy in acute ischemic stroke with atrial fibrillation: study protocol for a registry-based randomised controlled trial

N-terminal pro B-type natriuretic peptide in systematic screening for atrial fibrillation

Svennberg, Emma; Henriksson, Peter; Engdahl, Johan; Hijazi, Ziad et al.

Ingår i Heart, s. 1271-1277, 2017

• DOI för N-terminal pro B-type natriuretic peptide in systematic screening for atrial fibrillation

Repeated Measurements of Cardiac Biomarkers in Atrial Fibrillation and Validation of the ABC Stroke Score Over Time

Hijazi, Ziad; Lindahl, Bertil; Oldgren, Jonas; Andersson, Ulrika et al.

Ingår i Journal of the American Heart Association, 2017

• DOI för Repeated Measurements of Cardiac Biomarkers in Atrial Fibrillation and Validation of the ABC Stroke Score Over Time

Application of Biomarkers for Risk Stratification in Patients with Atrial Fibrillation

Hijazi, Ziad; Oldgren, Jonas; Siegbahn, Agneta; Wallentin, Lars

Ingår i Clinical Chemistry, s. 152-164, 2017

• DOI för Application of Biomarkers for Risk Stratification in Patients with Atrial Fibrillation

Risk of stroke in women and men with atrial fibrillation and only one additional CHA2DS2-VASC risk factor

Tomasdottir, Maria; Friberg, Leif; Hijazi, Ziad; Lindbäck, Johan et al.

Ingår i Journal of the American College of Cardiology, s. 327-327, 2017

• DOI för Risk of stroke in women and men with atrial fibrillation and only one additional CHA2DS2-VASC risk factor

Efficacy and Safety of Apixaban Compared With Warfarin in Patients With Atrial Fibrillation in Relation to Renal Function Over Time: Insights From the ARISTOTLE Randomized Clinical Trial

Hijazi, Ziad; Hohnloser, Stefan H; Andersson, Ulrika; Alexander, John H et al.

Ingår i JAMA cardiology, s. 451-460, 2016

• DOI för Efficacy and Safety of Apixaban Compared With Warfarin in Patients With Atrial Fibrillation in Relation to Renal Function Over Time: Insights From the ARISTOTLE Randomized Clinical Trial

Performance and Validation of a Novel Biomarker-Based Stroke Risk Score for Atrial Fibrillation

Oldgren, Jonas; Hijazi, Ziad; Lindbäck, Johan; Alexander, John H et al.

Ingår i Circulation, s. 1697-1707, 2016

• DOI för Performance and Validation of a Novel Biomarker-Based Stroke Risk Score for Atrial Fibrillation

NT-proBNP is a powerful predictor for incident atrial fibrillation: Validation of a multimarker approach

Svennberg, Emma; Lindahl, Bertil; Berglund, Lars; Eggers, Kai M. et al.

Ingår i International Journal of Cardiology, s. 74-81, 2016

• DOI för NT-proBNP is a powerful predictor for incident atrial fibrillation: Validation of a multimarker approach

Renal Function in Atrial Fibrillation A Multifaceted Dilemma

Hijazi, Ziad; Wallentin, Lars

Ingår i Circulation, s. 48-51, 2016

• DOI för Renal Function in Atrial Fibrillation A Multifaceted Dilemma

Cardiac biomarkers and left ventricular hypertrophy in relation to outcomes in patients with atrial fibrillation: experiences from the RELY trial

Hijazi, Ziad; Verdecchia, P.; Oldgren, Jonas; Andersson, Ulrika et al.

Ingår i EUROPEAN HEART JOURNAL, s. 47-47, 2016

External Validation Of The Biomarker-Based ABC-Bleeding Risk Score For Atrial Fibrillation

Hijazi, Ziad; Oldgren, Jonas; Lindbäck, Johan; Alexander, John et al.

Ingår i Journal of the American College of Cardiology, s. 893-893, 2016

External Validation Of The Biomarker-Based ABC-Stroke Risk Score For Atrial Fibrillation

Oldgren, Jonas; Hijazi, Ziad; Lindbäck, Johan; Alexander, John et al.

Ingår i Journal of the American College of Cardiology, s. 879-879, 2016

The 'obesity paradox' in atrial fibrillation: observations from the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) trial

Sandhu, Roopinder K.; Ezekowitz, Justin; Andersson, Ulrika; Alexander, John H. et al.

Ingår i European Heart Journal, s. 2869-2878, 2016

• DOI för The 'obesity paradox' in atrial fibrillation: observations from the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) trial

Apixaban 5 mg Twice Daily and Clinical Outcomes in Patients With Atrial Fibrillation and Advanced Age, Low Body Weight, or High Creatinine: A Secondary Analysis of a Randomized Clinical Trial

Alexander, John H; Andersson, Ulrika; Lopes, Renato D; Hijazi, Ziad et al.

Ingår i JAMA cardiology, s. 673-681, 2016

• DOI för Apixaban 5 mg Twice Daily and Clinical Outcomes in Patients With Atrial Fibrillation and Advanced Age, Low Body Weight, or High Creatinine: A Secondary Analysis of a Randomized Clinical Trial

Biomarkers of inflammation and risk of cardiovascular events in anticoagulated patients with atrial fibrillation

Hijazi, Ziad; Aulin, Julia; Andersson, Ulrika; Alexander, John H. et al.

Ingår i Heart, s. 508-517, 2016

• DOI för Biomarkers of inflammation and risk of cardiovascular events in anticoagulated patients with atrial fibrillation

The ABC risk score for patients with atrial fibrillation Reply

Hijazi, Ziad; Oldgren, Jonas; Lindbäck, Johan; Siegbahn, Agneta et al.

Ingår i The Lancet, s. 1980-1981, 2016

Growth differentiation factor 15 is an independent marker of risk of major bleeding in atrial fibrillation: insights from the RE-LY trial

Hijazi, Ziad; Oldgren, Jonas; Andersson, Ulrika; Connolly, S. J. et al.

s. 429-429, 2016

The ABC (age, biomarkers, clinical history) stroke risk score: a biomarker-based risk score for predicting stroke in atrial fibrillation

Hijazi, Ziad; Lindbäck, Johan; Alexander, John H.; Hanna, Michael et al.

Ingår i European Heart Journal, s. 1582-1590, 2016

• DOI för The ABC (age, biomarkers, clinical history) stroke risk score: a biomarker-based risk score for predicting stroke in atrial fibrillation

The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study

Hijazi, Ziad; Oldgren, Jonas; Lindbäck, Johan; Alexander, John H. et al.

Ingår i The Lancet, s. 2302-2311, 2016

• DOI för The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study

Efficacy and safety of apixaban compared with warfarin in relation to renal function over time in patients with atrial fibrillation: Insights from the ARISTOTLE trial

Hijazi, Ziad; Hohnloser, S. H.; Andersson, Ulrika; Alexander, J. H. et al.

Ingår i European Heart Journal, s. 339-339, 2015

Stroke and bleeding outcomes with apixaban versus warfarin in patients with high creatinine, low body weight or high age receiving standard dose apixaban for stroke prevention in atrial fibrillation

Alexander, J.; Andersson, Ulrika; Lopes, R. D.; Hijazi, Ziad et al.

Ingår i European Heart Journal, s. 345-345, 2015

External validation of the biomarker-based ABC-stroke risk score for atrial fibrillation

Hijazi, Ziad; Lindbäck, Johan; Östlund, Olof Petter; Siegbahn, Agneta et al.

Ingår i European Heart Journal, s. 710-711, 2015

Comparison of Cardiac Troponins I and T Measured with High-Sensitivity Methods for Evaluation of Prognosis in Atrial Fibrillation: An ARISTOTLE Substudy

Hijazi, Ziad; Siegbahn, Agneta; Andersson, Ulrika; Lindahl, Bertil et al.

Ingår i Clinical Chemistry, s. 368-378, 2015

• DOI för Comparison of Cardiac Troponins I and T Measured with High-Sensitivity Methods for Evaluation of Prognosis in Atrial Fibrillation: An ARISTOTLE Substudy

Stora studier av NOAK visar på gott och säkert strokeskydd

Hijazi, Ziad; Oldgren, Jonas

Ingår i Läkartidningen, 2015

Reply: Anticoagulant-Related Nephropathy

Böhm, Michael; Ezekowitz, Michael D; Connolly, Stuart J; Eikelboom, John W et al.

Ingår i Journal of the American College of Cardiology, s. 2682, 2015

• DOI för Reply: Anticoagulant-Related Nephropathy

Changes in Renal Function in Patients With Atrial Fibrillation An Analysis From the RE-LY Trial

Boehm, Michael; Ezekowitz, Michael D.; Connolly, Stuart J.; Eikelboom, John W. et al.

Ingår i Journal of the American College of Cardiology, s. 2481-2493, 2015

• DOI för Changes in Renal Function in Patients With Atrial Fibrillation An Analysis From the RE-LY Trial

Interleukin-6 and C-reactive protein and risk for death and cardiovascular events in patients with atrial fibrillation

Aulin, Julia; Siegbahn, Agneta; Hijazi, Ziad; Ezekowitz, Michael D. et al.

Ingår i American Heart Journal, s. 1151-1160, 2015

• DOI för Interleukin-6 and C-reactive protein and risk for death and cardiovascular events in patients with atrial fibrillation

Growth Differentiation Factor 15, a Marker of Oxidative Stress and Inflammation, for Risk Assessment in Patients With Atrial Fibrillation: Insights From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial

Wallentin, Lars; Hijazi, Ziad; Andersson, Ulrika; Alexander, John H. et al.

Ingår i Circulation, s. 1847-1858, 2014

• DOI för Growth Differentiation Factor 15, a Marker of Oxidative Stress and Inflammation, for Risk Assessment in Patients With Atrial Fibrillation: Insights From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial

Interleukin-6 and C-reactive protein and risk for cardiovascular events and death in anticoagulated patients with atrial fibrillation

Aulin, Julia; Hijazi, Ziad; Andersson, Ulrika; Gersh, B. J. et al.

Ingår i European Heart Journal, s. 1115-1116, 2014

Galectin-3 is associated with worse clinical outcome in patients with atrial fibrillation: A substudy from the ARISTOTLE trial

Åsberg, S.; Hijazi, Ziad; Siegbahn, Agneta; Andersson, Ulrika et al.

Ingår i European Heart Journal, s. 426-426, 2014

A new biomarker based risk score for predicting major bleeding in atrial fibrillation - the ABC (age, biomarkers, current disease) risk score

Hijazi, Ziad; Lindbäck, Johan; Siegbahn, Agneta; Alexander, J. H. et al.

Ingår i European Heart Journal, s. 357-357, 2014

Response to Letter Regarding Article, "Efficacy and Safety of Dabigatran Compared With Warfarin in Relation to Baseline Renal Function in Patients With Atrial Fibrillation: A RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) Trial Analysis"

Hijazi, Ziad; Hohnloser, Stefan H.; Oldgren, Jonas; Andersson, Ulrika et al.

Ingår i Circulation, 2014

• DOI för Response to Letter Regarding Article, "Efficacy and Safety of Dabigatran Compared With Warfarin in Relation to Baseline Renal Function in Patients With Atrial Fibrillation: A RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) Trial Analysis"

High Sensitivity Troponin T and Risk Stratification in Patients with Atrial Fibrillation during Treatment with Apixaban or Warfarin

Hijazi, Ziad; Wallentin, Lars; Siegbahn, Agneta; Andersson, Ulrika et al.

Ingår i Journal of the American College of Cardiology, s. 52-61, 2014

• DOI för High Sensitivity Troponin T and Risk Stratification in Patients with Atrial Fibrillation during Treatment with Apixaban or Warfarin

Importance of Persistent Elevation of Cardiac Biomarkers in Atrial Fibrillation: a RE-LY Substudy

Hijazi, Ziad; Oldgren, Jonas; Andersson, Ulrika; Connolly, Stuart J. et al.

Ingår i Heart, s. 1193-1200, 2014

• DOI för Importance of Persistent Elevation of Cardiac Biomarkers in Atrial Fibrillation: a RE-LY Substudy

Antikoagulation vid akut stroke med förmaksflimmer Fem frågor bör besvaras innan behandlingen kan anses vara evidensbaserad: [Anticoagulation in acute stroke with atrial fibrillation. Five questions should be answered before the treatment can be considered evidence-based].

Terént, Andreas; Åsberg, Signild; Hijazi, Ziad

Ingår i Läkartidningen, s. 872-874, 2014

Efficacy and Safety of Dabigatran Compared With Warfarin in Relation to Baseline Renal Function in Patients With Atrial Fibrillation A RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) Trial Analysis

Hijazi, Ziad; Hohnloser, Stefan H.; Oldgren, Jonas; Andersson, Ulrika et al.

Ingår i Circulation, s. 961-970, 2014

• DOI för Efficacy and Safety of Dabigatran Compared With Warfarin in Relation to Baseline Renal Function in Patients With Atrial Fibrillation A RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) Trial Analysis

High-Sensitivity Troponin I for Risk Assessment in Patients With Atrial Fibrillation Insights From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial

Hijazi, Ziad; Siegbahn, Agneta; Andersson, Ulrika; Granger, Christopher B. et al.

Ingår i Circulation, s. 625-634, 2014

• DOI för High-Sensitivity Troponin I for Risk Assessment in Patients With Atrial Fibrillation Insights From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial

N-Terminal Pro-B-Type Natriuretic Peptide for Risk Assessment in Patients With Atrial Fibrillation: Insights from the ARISTOTLE trial

Hijazi, Ziad; Wallentin, Lars; Siegbahn, Agneta; Andersson, Ulrika et al.

Ingår i Journal of the American College of Cardiology, s. 2274-2284, 2013

• DOI för N-Terminal Pro-B-Type Natriuretic Peptide for Risk Assessment in Patients With Atrial Fibrillation: Insights from the ARISTOTLE trial

Biomarkers in atrial fibrillation: a clinical review

Hijazi, Ziad; Oldgren, Jonas; Siegbahn, Agneta; Granger, Christopher B et al.

Ingår i European Heart Journal, s. 1475-1480, 2013

• DOI för Biomarkers in atrial fibrillation: a clinical review

New Risk Markers in Atrial Fibrillation

Hijazi, Ziad

2013

• Ladda ner fulltext (pdf) av New Risk Markers in Atrial Fibrillation

Reply: Higher N-Terminal Pro-B-Type Natriuretic Peptide May Be Related to Very Different Conditions

Hijazi, Ziad; Granger, Christopher B.; Wallentin, Lars

Ingår i Journal of the American College of Cardiology, s. 1635-1636, 2013

• DOI för Reply: Higher N-Terminal Pro-B-Type Natriuretic Peptide May Be Related to Very Different Conditions

Response to Letter Regarding Article, "Cardiac Biomarkers Are Associated With an Increased Risk of Stroke and Death in Patients With Atrial Fibrillation: A Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Substudy"

Hijazi, Ziad; Oldgren, Jonas; Wallentin, Lars; Andersson, Ulrika et al.

Ingår i Circulation, 2013

• DOI för Response to Letter Regarding Article, "Cardiac Biomarkers Are Associated With an Increased Risk of Stroke and Death in Patients With Atrial Fibrillation: A Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Substudy"

Combining High Sensitivity Troponin I and T Measurements Improves Prediction of Long-Term Clinical Outcomes in Patients With Atrial Fibrillation - An Aristotle Substudy

Hijazi, Ziad; Siegbahn, Agneta; Andersson, Ulrika; Granger, Christopher B. et al.

Ingår i Circulation, 2013

Cardiac Biomarkers Are Associated With an Increased Risk of Stroke and Death in Patients With Atrial Fibrillation: A Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Substudy

Hijazi, Ziad; Oldgren, Jonas; Andersson, Ulrika; Connolly, Stuart J. et al.

Ingår i Circulation, s. 1605-1616, 2012

• DOI för Cardiac Biomarkers Are Associated With an Increased Risk of Stroke and Death in Patients With Atrial Fibrillation: A Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Substudy

Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial

Hohnloser, Stefan H.; Hijazi, Ziad; Thomas, Laine; Alexander, John H. et al.

Ingår i European Heart Journal, s. 2821-2830, 2012

• DOI för Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial

Screening of plasma biomarkers for heart failure hospitalizations and heart failure subtype in patients with atrial fibrillation

Pol, Tymon; Lindbäck, Johan; Oldgren, Jonas; Alexander, John H. et al.

Transforming Atrial Fibrillation Management by Targeting Comorbidities and Reducing Atrial Fibrillation Burden: the 10th AFNET/EHRA Consensus Conference.

Svennberg, Emma; Merino, Jose Luis; Andrade, Jason; Anselmino, Matteo et al.

Ingår i Europace, 2025

• DOI för Transforming Atrial Fibrillation Management by Targeting Comorbidities and Reducing Atrial Fibrillation Burden: the 10th AFNET/EHRA Consensus Conference.

Risk and protective factors for stroke and transient ischaemic attack in patients with atrial fibrillation: an umbrella review of meta-analyses.

Kylhammar, Axel; Tsartsalis, Dimitrios; Hijazi, Ziad; Aggeli, Constantina et al.

Ingår i Heart, 2025

• DOI för Risk and protective factors for stroke and transient ischaemic attack in patients with atrial fibrillation: an umbrella review of meta-analyses.

Biomarker-Based ABC-AF Risk Scores for Personalized Treatment to Reduce Stroke or Death in Atrial Fibrillation: A Registry-Based, Multicenter, Randomized, Controlled Study

Oldgren, Jonas; Hijazi, Ziad; Arheden, Hakan; Bjorkenheim, Anna et al.

Ingår i Circulation, s. 1457-1469, 2025

• DOI för Biomarker-Based ABC-AF Risk Scores for Personalized Treatment to Reduce Stroke or Death in Atrial Fibrillation: A Registry-Based, Multicenter, Randomized, Controlled Study
• Ladda ner fulltext (pdf) av Biomarker-Based ABC-AF Risk Scores for Personalized Treatment to Reduce Stroke or Death in Atrial Fibrillation: A Registry-Based, Multicenter, Randomized, Controlled Study

Differences in inflammation biomarkers between patients with paroxysmal and persistent atrial fibrillation in the femoral vein and coronary sinus blood samples; a cohort study.

Valera Soria, Carlos; Carlhäll, Carl-Johan; Karlsson, Lars O; Lindbäck, Johan et al.

Ingår i European Heart Journal Open, 2025

• DOI för Differences in inflammation biomarkers between patients with paroxysmal and persistent atrial fibrillation in the femoral vein and coronary sinus blood samples; a cohort study.

Rationale and design of a registry-based randomized controlled study of personalized biomarker-based risk score-guided stroke prevention treatment in atrial fibrillation

Hijazi, Ziad; Wallentin, Lars; Arheden, Hakan; Bjorkenheim, Anna et al.

Ingår i American Heart Journal, s. 161-169, 2025

• DOI för Rationale and design of a registry-based randomized controlled study of personalized biomarker-based risk score-guided stroke prevention treatment in atrial fibrillation
• Ladda ner fulltext (pdf) av Rationale and design of a registry-based randomized controlled study of personalized biomarker-based risk score-guided stroke prevention treatment in atrial fibrillation

Transforming Atrial Fibrillation Management by Targeting Comorbidities and Reducing Atrial Fibrillation Burden: the 10th AFNET/EHRA Consensus Conference.

Svennberg, Emma; Merino, Jose Luis; Andrade, Jason; Anselmino, Matteo et al.

Ingår i Europace, 2025

• DOI för Transforming Atrial Fibrillation Management by Targeting Comorbidities and Reducing Atrial Fibrillation Burden: the 10th AFNET/EHRA Consensus Conference.

Risk and protective factors for stroke and transient ischaemic attack in patients with atrial fibrillation: an umbrella review of meta-analyses.

Kylhammar, Axel; Tsartsalis, Dimitrios; Hijazi, Ziad; Aggeli, Constantina et al.

Ingår i Heart, 2025

• DOI för Risk and protective factors for stroke and transient ischaemic attack in patients with atrial fibrillation: an umbrella review of meta-analyses.

Biomarker-Based ABC-AF Risk Scores for Personalized Treatment to Reduce Stroke or Death in Atrial Fibrillation: A Registry-Based, Multicenter, Randomized, Controlled Study

Oldgren, Jonas; Hijazi, Ziad; Arheden, Hakan; Bjorkenheim, Anna et al.

Ingår i Circulation, s. 1457-1469, 2025

• DOI för Biomarker-Based ABC-AF Risk Scores for Personalized Treatment to Reduce Stroke or Death in Atrial Fibrillation: A Registry-Based, Multicenter, Randomized, Controlled Study
• Ladda ner fulltext (pdf) av Biomarker-Based ABC-AF Risk Scores for Personalized Treatment to Reduce Stroke or Death in Atrial Fibrillation: A Registry-Based, Multicenter, Randomized, Controlled Study

Differences in inflammation biomarkers between patients with paroxysmal and persistent atrial fibrillation in the femoral vein and coronary sinus blood samples; a cohort study.

Valera Soria, Carlos; Carlhäll, Carl-Johan; Karlsson, Lars O; Lindbäck, Johan et al.

Ingår i European Heart Journal Open, 2025

• DOI för Differences in inflammation biomarkers between patients with paroxysmal and persistent atrial fibrillation in the femoral vein and coronary sinus blood samples; a cohort study.

Rationale and design of a registry-based randomized controlled study of personalized biomarker-based risk score-guided stroke prevention treatment in atrial fibrillation

Hijazi, Ziad; Wallentin, Lars; Arheden, Hakan; Bjorkenheim, Anna et al.

Ingår i American Heart Journal, s. 161-169, 2025

• DOI för Rationale and design of a registry-based randomized controlled study of personalized biomarker-based risk score-guided stroke prevention treatment in atrial fibrillation
• Ladda ner fulltext (pdf) av Rationale and design of a registry-based randomized controlled study of personalized biomarker-based risk score-guided stroke prevention treatment in atrial fibrillation

Biomarker-Based Model for Prediction of Ischemic Stroke in Patients With Atrial Fibrillation

Wallentin, Lars; Lindbäck, Johan; Hijazi, Ziad; Oldgren, Jonas et al.

Ingår i Journal of the American College of Cardiology, 2025

• DOI för Biomarker-Based Model for Prediction of Ischemic Stroke in Patients With Atrial Fibrillation

Randomized Invitation to Systematic NT-proBNP and ECG Screening in 75-Year-Olds to Detect Atrial Fibrillation: STROKESTOP II

Kemp Gudmundsdottir, Katrin; Svennberg, Emma; Friberg, Leif; Hygrell, Tove et al.

Ingår i Circulation, s. 1837-1846, 2024

• DOI för Randomized Invitation to Systematic NT-proBNP and ECG Screening in 75-Year-Olds to Detect Atrial Fibrillation: STROKESTOP II

Heart Failure Risk Assessment Using Biomarkers in Patients With Atrial Fibrillation: Analysis From COMBINE-AF

Haller, Paul M.; Jarolim, Petr; Palazzolo, Michael G.; Bellavia, Andrea et al.

Ingår i Journal of the American College of Cardiology, s. 1528-1540, 2024

• DOI för Heart Failure Risk Assessment Using Biomarkers in Patients With Atrial Fibrillation: Analysis From COMBINE-AF

Repeated Measurement of the Novel Atrial Biomarker BMP10 (Bone Morphogenetic Protein 10) Refines Risk Stratification in Anticoagulated Patients With Atrial Fibrillation: Insights From the ARISTOTLE Trial

Gkarmiris, Konstantinos I.; Lindbäck, Johan; Alexander, John H.; Granger, Christopher B. et al.

Ingår i Journal of the American Heart Association, 2024

• DOI för Repeated Measurement of the Novel Atrial Biomarker BMP10 (Bone Morphogenetic Protein 10) Refines Risk Stratification in Anticoagulated Patients With Atrial Fibrillation: Insights From the ARISTOTLE Trial
• Ladda ner fulltext (pdf) av Repeated Measurement of the Novel Atrial Biomarker BMP10 (Bone Morphogenetic Protein 10) Refines Risk Stratification in Anticoagulated Patients With Atrial Fibrillation: Insights From the ARISTOTLE Trial

Longer and better lives for patients with atrial fibrillation: the 9th AFNET/EHRA consensus conference

Linz, Dominik; Andrade, Jason G.; Arbelo, Elena; Boriani, Giuseppe et al.

Ingår i Europace, 2024

• DOI för Longer and better lives for patients with atrial fibrillation: the 9th AFNET/EHRA consensus conference
• Ladda ner fulltext (pdf) av Longer and better lives for patients with atrial fibrillation: the 9th AFNET/EHRA consensus conference

Neurofilament Light Chain and Risk of Stroke in Patients With Atrial Fibrillation

Aulin, Julia; Sjölin, Karl; Lindbäck, Johan; Benz, Alexander P et al.

Ingår i Circulation, s. 1090-1100, 2024

• DOI för Neurofilament Light Chain and Risk of Stroke in Patients With Atrial Fibrillation

Data standards for atrial fibrillation/flutter and catheter ablation: The European Unified Registries for Heart Care Evaluation and Randomized Trials (EuroHeart)

Batra, Gorav; Aktaa, Suleman; Camm, A. John; Costa, Francisco et al.

Ingår i European Heart Journal - Quality of Care and Clinical Outcomes, s. 609-620, 2023

• DOI för Data standards for atrial fibrillation/flutter and catheter ablation: The European Unified Registries for Heart Care Evaluation and Randomized Trials (EuroHeart)
• Ladda ner fulltext (pdf) av Data standards for atrial fibrillation/flutter and catheter ablation: The European Unified Registries for Heart Care Evaluation and Randomized Trials (EuroHeart)

ABC-AF-Stroke score predicts thromboembolism in non-anticoagulated patients following successful atrial fibrillation ablation: a report from the Chinese Atrial Fibrillation Registry

Wang, Yufeng; Jiang, Chao; He, Liu; Du, Xin et al.

Ingår i Chinese Medical Journal, s. 2451-2458, 2023

• DOI för ABC-AF-Stroke score predicts thromboembolism in non-anticoagulated patients following successful atrial fibrillation ablation: a report from the Chinese Atrial Fibrillation Registry
• Ladda ner fulltext (pdf) av ABC-AF-Stroke score predicts thromboembolism in non-anticoagulated patients following successful atrial fibrillation ablation: a report from the Chinese Atrial Fibrillation Registry

Plasma angiopoietin-2 and its association with heart failure in patients with atrial fibrillation

Benz, Alexander P.; Hijazi, Ziad; Lindbäck, Johan; Connolly, Stuart J. et al.

Ingår i Europace, 2023

• DOI för Plasma angiopoietin-2 and its association with heart failure in patients with atrial fibrillation
• Ladda ner fulltext (pdf) av Plasma angiopoietin-2 and its association with heart failure in patients with atrial fibrillation

Direct Oral Anticoagulants Versus Warfarin Across the Spectrum of Kidney Function: Patient-Level Network Meta-Analyses From COMBINE AF

Harrington, Josephine; Carnicelli, Anthony P.; Hua, Kaiyuan; Wallentin, Lars et al.

Ingår i Circulation, s. 1748-1757, 2023

• DOI för Direct Oral Anticoagulants Versus Warfarin Across the Spectrum of Kidney Function: Patient-Level Network Meta-Analyses From COMBINE AF

Heart rate and death and hospitalization for heart failure in patients with persistent or permanent atrial fibrillation: Insights from the ARISTOTLE trial

Vinereanu, Dragos; Wojdyla, Daniel M.; Alexander, John H.; Lopes, Renato D. et al.

Ingår i American Heart Journal, s. 132-136, 2023

• DOI för Heart rate and death and hospitalization for heart failure in patients with persistent or permanent atrial fibrillation: Insights from the ARISTOTLE trial

Outcomes of patients with atrial fibrillation and ischemic stroke while on oral anticoagulation

Benz, Alexander P.; Hohnloser, Stefan H.; Eikelboom, John W.; Carnicelli, Anthony P. et al.

Ingår i European Heart Journal, s. 1807-1814, 2023

• DOI för Outcomes of patients with atrial fibrillation and ischemic stroke while on oral anticoagulation

Individual net clinical outcome with oral anticoagulation in atrial fibrillation using the ABC-AF risk scores

Hijazi, Ziad; Lindbäck, Johan; Oldgren, Jonas; Benz, Alexander P. et al.

Ingår i American Heart Journal, s. 55-63, 2023

• DOI för Individual net clinical outcome with oral anticoagulation in atrial fibrillation using the ABC-AF risk scores
• Ladda ner fulltext (pdf) av Individual net clinical outcome with oral anticoagulation in atrial fibrillation using the ABC-AF risk scores

Early Versus Delayed Non-Vitamin K Antagonist Oral Anticoagulant Therapy After Acute Ischemic Stroke in Atrial Fibrillation (TIMING): A Registry-Based Randomized Controlled Noninferiority Study

Oldgren, Jonas; Åsberg, Signild; Hijazi, Ziad; Wester, Per et al.

Ingår i Circulation, s. 1056-1066, 2022

• DOI för Early Versus Delayed Non-Vitamin K Antagonist Oral Anticoagulant Therapy After Acute Ischemic Stroke in Atrial Fibrillation (TIMING): A Registry-Based Randomized Controlled Noninferiority Study
• Ladda ner fulltext (pdf) av Early Versus Delayed Non-Vitamin K Antagonist Oral Anticoagulant Therapy After Acute Ischemic Stroke in Atrial Fibrillation (TIMING): A Registry-Based Randomized Controlled Noninferiority Study

The ABC-Stroke Score Refines Stroke Risk Stratification in Patients With Atrial Fibrillation at the Emergency Department

Niederdöckl, Jan; Oppenauer, Julia; Schnaubelt, Sebastian; Cacioppo, Filippo et al.

Ingår i Frontiers in Medicine, 2022

• DOI för The ABC-Stroke Score Refines Stroke Risk Stratification in Patients With Atrial Fibrillation at the Emergency Department
• Ladda ner fulltext (pdf) av The ABC-Stroke Score Refines Stroke Risk Stratification in Patients With Atrial Fibrillation at the Emergency Department

Bone morphogenetic protein 10: a novel risk marker of ischaemic stroke in patients with atrial fibrillation

Hijazi, Ziad; Benz, Alexander P.; Lindbäck, Johan; Alexander, John H. et al.

Ingår i European Heart Journal, s. 208-218, 2022

• DOI för Bone morphogenetic protein 10: a novel risk marker of ischaemic stroke in patients with atrial fibrillation
• Ladda ner fulltext (pdf) av Bone morphogenetic protein 10: a novel risk marker of ischaemic stroke in patients with atrial fibrillation

Association of GDF-15, hs-cTnT and NT-proBNP with coronary artery disease in patients undergoing elective angiography

Souaid, Tarek; Hijazi, Ziad; Barakett, Vanda; Sarkis, Antoine et al.

Ingår i Future Cardiology, s. 635-646, 2022

• DOI för Association of GDF-15, hs-cTnT and NT-proBNP with coronary artery disease in patients undergoing elective angiography

Duration of Anticoagulation Interruption Before Invasive Procedures and Outcomes in Patients With Atrial Fibrillation: Insights From the ARISTOTLE Trial

Al-Khatib, Sana M.; Wojdyla, Daniel M.; Granger, Christopher B.; Wallentin, Lars et al.

Ingår i Circulation, s. 958-960, 2022

• DOI för Duration of Anticoagulation Interruption Before Invasive Procedures and Outcomes in Patients With Atrial Fibrillation: Insights From the ARISTOTLE Trial

Direct Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation: Patient-Level Network Meta-Analyses of Randomized Clinical Trials With Interaction Testing by Age and Sex

Carnicelli, Anthony P.; Hong, Hwanhee; Connolly, Stuart J.; Eikelboom, John et al.

Ingår i Circulation, s. 242-255, 2022

• DOI för Direct Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation: Patient-Level Network Meta-Analyses of Randomized Clinical Trials With Interaction Testing by Age and Sex

Biomarkers and heart failure events in patients with atrial fibrillation in the ARISTOTLE trial evaluated by a multi-state model

Aulin, Julia; Hijazi, Ziad; Lindbäck, Johan; Alexander, John H. et al.

Ingår i American Heart Journal, s. 13-24, 2022

• DOI för Biomarkers and heart failure events in patients with atrial fibrillation in the ARISTOTLE trial evaluated by a multi-state model
• Ladda ner fulltext (pdf) av Biomarkers and heart failure events in patients with atrial fibrillation in the ARISTOTLE trial evaluated by a multi-state model

Risk markers of incident atrial fibrillation in patients with coronary heart disease

Tomasdottir, Maria; Held, Claes; Hadziosmanovic, Nermin; Westerbergh, Johan et al.

Ingår i American Heart Journal, s. 92-101, 2021

• DOI för Risk markers of incident atrial fibrillation in patients with coronary heart disease
• Ladda ner fulltext (pdf) av Risk markers of incident atrial fibrillation in patients with coronary heart disease

Apixaban or Vitamin K Antagonists and Aspirin or Placebo According to Kidney Function in Patients With Atrial Fibrillation After Acute Coronary Syndrome or Percutaneous Coronary Intervention: Insights From the AUGUSTUS Trial

Hijazi, Ziad; Alexander, John H.; Li, Zhuokai; Wojdyla, Daniel M. et al.

Ingår i Circulation, s. 1215-1223, 2021

• DOI för Apixaban or Vitamin K Antagonists and Aspirin or Placebo According to Kidney Function in Patients With Atrial Fibrillation After Acute Coronary Syndrome or Percutaneous Coronary Intervention: Insights From the AUGUSTUS Trial

Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Left Ventricular Hypertrophy: Insights From the ARISTOTLE Trial

Al-Khatib, Sana M.; Mulder, Hillary; Wojdyla, Daniel; Lopes, Renato D. et al.

Ingår i Circulation, s. 359-361, 2021

• DOI för Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Left Ventricular Hypertrophy: Insights From the ARISTOTLE Trial

Evaluation of the prognostic value of GDF-15, ABC-AF-bleeding score and ABC-AF-death score in patients with atrial fibrillation across different geographical areas

Pol, Tymon; Hijazi, Ziad; Lindbäck, Johan; Alexander, John H. et al.

Ingår i Open heart, 2021

• DOI för Evaluation of the prognostic value of GDF-15, ABC-AF-bleeding score and ABC-AF-death score in patients with atrial fibrillation across different geographical areas
• Ladda ner fulltext (pdf) av Evaluation of the prognostic value of GDF-15, ABC-AF-bleeding score and ABC-AF-death score in patients with atrial fibrillation across different geographical areas

Biomarker-Based Risk Prediction With the ABC-AF Scores in Patients With Atrial Fibrillation Not Receiving Oral Anticoagulation

Benz, Alexander P.; Hijazi, Ziad; Lindbäck, Johan; Connolly, Stuart J. et al.

Ingår i Circulation, s. 1863-1873, 2021

• DOI för Biomarker-Based Risk Prediction With the ABC-AF Scores in Patients With Atrial Fibrillation Not Receiving Oral Anticoagulation

Multiplex protein screening of biomarkers associated with major bleeding in patients with atrial fibrillation treated with oral anticoagulation.

Siegbahn, Agneta; Lindbäck, Johan; Hijazi, Ziad; Åberg, Mikael et al.

Ingår i Journal of Thrombosis and Haemostasis, s. 2726-2737, 2021

• DOI för Multiplex protein screening of biomarkers associated with major bleeding in patients with atrial fibrillation treated with oral anticoagulation.
• Ladda ner fulltext (pdf) av Multiplex protein screening of biomarkers associated with major bleeding in patients with atrial fibrillation treated with oral anticoagulation.

Using multimarker screening to identify biomarkers associated with cardiovascular death in patients with atrial fibrillation.

Pol, Tymon; Hijazi, Ziad; Lindbäck, Johan; Oldgren, Jonas et al.

Ingår i Cardiovascular Research, s. 2112-2123, 2021

• DOI för Using multimarker screening to identify biomarkers associated with cardiovascular death in patients with atrial fibrillation.
• Ladda ner fulltext (pdf) av Using multimarker screening to identify biomarkers associated with cardiovascular death in patients with atrial fibrillation.

Biomarker-based risk scores in atrial fibrillation

Hijazi, Ziad; Mills, Nicholas L; Mueller, Christian

Ingår i European Heart Journal, s. 1084-1085, 2021

• DOI för Biomarker-based risk scores in atrial fibrillation

Natriuretic peptides and incident atrial fibrillation

Tomasdottir, Maria; Held, Claes; Wallentin, Lars; Hijazi, Ziad

Ingår i American Heart Journal, s. 1-1, 2021

• DOI för Natriuretic peptides and incident atrial fibrillation

Cardiac troponin is associated with cardiac outcomes in men and women with atrial fibrillation, insights from the ARISTOTLE trial

Rosjo, H.; Hijazi, Ziad; Omland, T.; Westerbergh, Johan et al.

Ingår i Journal of Internal Medicine, s. 248-259, 2020

• DOI för Cardiac troponin is associated with cardiac outcomes in men and women with atrial fibrillation, insights from the ARISTOTLE trial
• Ladda ner fulltext (pdf) av Cardiac troponin is associated with cardiac outcomes in men and women with atrial fibrillation, insights from the ARISTOTLE trial

Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Advanced Chronic Kidney Disease

Stanifer, John W.; Pokorney, Sean D.; Chertow, Glenn M.; Hohnloser, Stefan H. et al.

Ingår i Circulation, s. 1384-1392, 2020

• DOI för Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Advanced Chronic Kidney Disease

Angiotensin-converting enzyme 2 (ACE2) levels in relation to risk factors for COVID-19 in two large cohorts of patients with atrial fibrillation.

Wallentin, Lars; Lindbäck, Johan; Eriksson, Niclas; Hijazi, Ziad et al.

Ingår i European Heart Journal, s. 4037-4046, 2020

• DOI för Angiotensin-converting enzyme 2 (ACE2) levels in relation to risk factors for COVID-19 in two large cohorts of patients with atrial fibrillation.

Serial measurement of interleukin-6 and risk of mortality in anticoagulated patients with atrial fibrillation: Insights from ARISTOTLE and RE-LY trials.

Aulin, Julia; Hijazi, Ziad; Siegbahn, Agneta; Andersson, Ulrika et al.

Ingår i Journal of Thrombosis and Haemostasis, s. 2287-2295, 2020

• DOI för Serial measurement of interleukin-6 and risk of mortality in anticoagulated patients with atrial fibrillation: Insights from ARISTOTLE and RE-LY trials.
• Ladda ner fulltext (pdf) av Serial measurement of interleukin-6 and risk of mortality in anticoagulated patients with atrial fibrillation: Insights from ARISTOTLE and RE-LY trials.

Screening of Multiple Biomarkers Associated With Ischemic Stroke in Atrial Fibrillation

Hijazi, Ziad; Wallentin, Lars; Lindbäck, Johan; Alexander, John H. et al.

Ingår i Journal of the American Heart Association, 2020

• DOI för Screening of Multiple Biomarkers Associated With Ischemic Stroke in Atrial Fibrillation
• Ladda ner fulltext (pdf) av Screening of Multiple Biomarkers Associated With Ischemic Stroke in Atrial Fibrillation

Evaluation of the Age, Biomarkers, and Clinical History-Bleeding Risk Score in Patients With Atrial Fibrillation With Combined Aspirin and Anticoagulation Therapy Enrolled in the ARISTOTLE and RE-LY Trials

Hijazi, Ziad; Oldgren, Jonas; Lindbäck, Johan; Alexander, John H. et al.

Ingår i JAMA Network Open, 2020

• DOI för Evaluation of the Age, Biomarkers, and Clinical History-Bleeding Risk Score in Patients With Atrial Fibrillation With Combined Aspirin and Anticoagulation Therapy Enrolled in the ARISTOTLE and RE-LY Trials

Regional variation in clinical characteristics and outcomes in patients with atrial fibrillation: Findings from the ARISTOTLE trial

Bahit, M. Cecilia; Granger, Christopher B.; Alexander, John H.; Mulder, Hillary et al.

Ingår i International Journal of Cardiology, s. 53-58, 2020

• DOI för Regional variation in clinical characteristics and outcomes in patients with atrial fibrillation: Findings from the ARISTOTLE trial

Cardiovascular outcomes, bleeding risk, and achieved blood pressure in patients on long-term anticoagulation with the thrombin antagonist dabigatran or warfarin: data from the RE-LY trial

Böhm, Michael; Brueckmann, Martina; Eikelboom, John W.; Ezekowitz, Michael et al.

Ingår i European Heart Journal, s. 2848-2859, 2020

• DOI för Cardiovascular outcomes, bleeding risk, and achieved blood pressure in patients on long-term anticoagulation with the thrombin antagonist dabigatran or warfarin: data from the RE-LY trial

Stepwise mass screening for atrial fibrillation using N-terminal B-type natriuretic peptide: the STROKESTOP II study

Gudmundsdottir, Katrin Kemp; Fredriksson, Tove; Svennberg, Emma; Al-Khalili, Faris et al.

Ingår i Europace, s. 24-32, 2020

• DOI för Stepwise mass screening for atrial fibrillation using N-terminal B-type natriuretic peptide: the STROKESTOP II study
• Ladda ner fulltext (pdf) av Stepwise mass screening for atrial fibrillation using N-terminal B-type natriuretic peptide: the STROKESTOP II study

Association of Different Estimates of Renal Function With Cardiovascular Mortality and Bleeding in Atrial Fibrillation

Hijazi, Ziad; Granger, Christopher B.; Hohnloser, Stefan H.; Westerbergh, Johan et al.

Ingår i Journal of the American Heart Association, 2020

• DOI för Association of Different Estimates of Renal Function With Cardiovascular Mortality and Bleeding in Atrial Fibrillation

Risk of ischemic stroke and utility of CHA₂DS₂-VASc score in women and men with atrial fibrillation

Tomasdottir, Maria; Friberg, Leif; Hijazi, Ziad; Lindbäck, Johan et al.

Ingår i Clinical Cardiology, s. 1003-1009, 2019

• DOI för Risk of ischemic stroke and utility of CHA₂DS₂-VASc score in women and men with atrial fibrillation
• Ladda ner fulltext (pdf) av Risk of ischemic stroke and utility of CHA₂DS₂-VASc score in women and men with atrial fibrillation

International normalized ratio control and subsequent clinical outcomes in patients with atrial fibrillation using warfarin

Guimaraes, Patricia O.; Lopes, Renato D.; Alexander, John H.; Thomas, Laine et al.

Ingår i Journal of Thrombosis and Thrombolysis, s. 27-34, 2019

• DOI för International normalized ratio control and subsequent clinical outcomes in patients with atrial fibrillation using warfarin

Natriuretic peptide should be used as a routine tool for evaluation of patients with atrial fibrillation

Hijazi, Ziad; Wallentin, Lars

Ingår i Heart, s. 353-354, 2019

• DOI för Natriuretic peptide should be used as a routine tool for evaluation of patients with atrial fibrillation

Outcomes of apixaban versus warfarin in patients with atrial fibrillation and multi-morbidity: Insights from the ARISTOTLE trial

Alexander, Karen P; Brouwer, Marc A; Mulder, Hillary; Vinereanu, Dragos et al.

Ingår i American Heart Journal, s. 123-131, 2019

• DOI för Outcomes of apixaban versus warfarin in patients with atrial fibrillation and multi-morbidity: Insights from the ARISTOTLE trial

Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation

Lopes, Renato D.; Heizer, Gretchen; Aronson, Ronald; Vora, Amit N. et al.

Ingår i New England Journal of Medicine, s. 1509-1524, 2019

• DOI för Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation

Efficacy and Safety of Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Extremes in Body Weight: Insights From the ARISTOTLE Trial

Hohnloser, Stefan H.; Fudim, Marat; Alexander, John H.; Wojdyla, Daniel M. et al.

Ingår i Circulation, s. 2292-2300, 2019

• DOI för Efficacy and Safety of Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Extremes in Body Weight: Insights From the ARISTOTLE Trial

Cardiac Biomarkers and Left Ventricular Hypertrophy in Relation to Outcomes in Patients With Atrial Fibrillation: Experiences From the RE-LY Trial

Hijazi, Ziad; Verdecchia, Paolo; Oldgren, Jonas; Andersson, Ulrika et al.

Ingår i Journal of the American Heart Association, 2019

• DOI för Cardiac Biomarkers and Left Ventricular Hypertrophy in Relation to Outcomes in Patients With Atrial Fibrillation: Experiences From the RE-LY Trial
• Ladda ner fulltext (pdf) av Cardiac Biomarkers and Left Ventricular Hypertrophy in Relation to Outcomes in Patients With Atrial Fibrillation: Experiences From the RE-LY Trial

Obesity paradox on outcome in atrial fibrillation maintained even considering the prognostic influence of biomarkers: insights from the ARISTOTLE trial

Sandhu, Roopinder K.; Ezekowitz, Justin A.; Hijazi, Ziad; Westerbergh, Johan et al.

Ingår i Open heart, 2018

• DOI för Obesity paradox on outcome in atrial fibrillation maintained even considering the prognostic influence of biomarkers: insights from the ARISTOTLE trial
• Ladda ner fulltext (pdf) av Obesity paradox on outcome in atrial fibrillation maintained even considering the prognostic influence of biomarkers: insights from the ARISTOTLE trial

Use of Biomarkers to Predict Specific Causes of Death in Patients With Atrial Fibrillation: Insights From the ARISTOTLE Trial

Sharma, Abhinav; Hijazi, Ziad; Andersson, Ulrika; Al-Khatib, Sana M. et al.

Ingår i Circulation, s. 1666-1676, 2018

• DOI för Use of Biomarkers to Predict Specific Causes of Death in Patients With Atrial Fibrillation: Insights From the ARISTOTLE Trial

A biomarker-based risk score to predict death in patients with atrial fibrillation: the ABC (age, biomarkers, clinical history) death risk score

Hijazi, Ziad; Oldgren, Jonas; Lindbäck, Johan; Alexander, John H. et al.

Ingår i European Heart Journal, s. 477-485, 2018

• DOI för A biomarker-based risk score to predict death in patients with atrial fibrillation: the ABC (age, biomarkers, clinical history) death risk score
• Ladda ner fulltext (pdf) av A biomarker-based risk score to predict death in patients with atrial fibrillation: the ABC (age, biomarkers, clinical history) death risk score

New Biomarkers Associated With Cardiovascular Death In Patients With Atrial Fibrillation Using Multimarker Screening: Insights From The Aristotle Trial

Pol, Tymon; Hijazi, Ziad; Lindbäck, Johan; Oldgren, Jonas et al.

Ingår i Journal of the American College of Cardiology, s. 330-330, 2018

• DOI för New Biomarkers Associated With Cardiovascular Death In Patients With Atrial Fibrillation Using Multimarker Screening: Insights From The Aristotle Trial

Novel Prognostic Biomarkers For Ischemic Stroke In Patients With Atrial Fibrillation Using Multimarker Screening: Insights From The Aristotle Trial

Hijazi, Ziad; Pol, Tymon; Oldgren, Jonas; Lindbäck, Johan et al.

Ingår i Journal of the American College of Cardiology, s. 506-506, 2018

Efficacy and safety of dabigatran compared with warfarin in patients with atrial fibrillation in relation to renal function over time-A RE-LY trial analysis

Hijazi, Ziad; Hohnloser, Stefan H.; Oldgren, Jonas; Andersson, Ulrika et al.

Ingår i American Heart Journal, s. 169-177, 2018

• DOI för Efficacy and safety of dabigatran compared with warfarin in patients with atrial fibrillation in relation to renal function over time-A RE-LY trial analysis

Dyslipidemia and Risk of Cardiovascular Events in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Therapy: Insights From the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) Trial

Pol, Tymon; Held, Claes; Westerbergh, Johan; Lindbäck, Johan et al.

Ingår i Journal of the American Heart Association, 2018

• DOI för Dyslipidemia and Risk of Cardiovascular Events in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Therapy: Insights From the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) Trial

Comparison of bleeding risk scores in patients with atrial fibrillation: insights from the RE-LY trial

Proietti, M.; Hijazi, Ziad; Andersson, Ulrika; Connolly, S. J. et al.

Ingår i Journal of Internal Medicine, s. 282-292, 2018

• DOI för Comparison of bleeding risk scores in patients with atrial fibrillation: insights from the RE-LY trial

Growth-differentiation factor 15 and risk of major bleeding in atrial fibrillation: Insights from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial

Hijazi, Ziad; Oldgren, Jonas; Andersson, Ulrika; Connolly, Stuart J et al.

Ingår i American Heart Journal, s. 94-103, 2017

• DOI för Growth-differentiation factor 15 and risk of major bleeding in atrial fibrillation: Insights from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial

Timing of oral anticoagulant therapy in acute ischemic stroke with atrial fibrillation: study protocol for a registry-based randomised controlled trial

Åsberg, Signild; Hijazi, Ziad; Norrving, Bo; Terént, Andreas et al.

Ingår i Trials, 2017

• DOI för Timing of oral anticoagulant therapy in acute ischemic stroke with atrial fibrillation: study protocol for a registry-based randomised controlled trial
• Ladda ner fulltext (pdf) av Timing of oral anticoagulant therapy in acute ischemic stroke with atrial fibrillation: study protocol for a registry-based randomised controlled trial

N-terminal pro B-type natriuretic peptide in systematic screening for atrial fibrillation

Svennberg, Emma; Henriksson, Peter; Engdahl, Johan; Hijazi, Ziad et al.

Ingår i Heart, s. 1271-1277, 2017

• DOI för N-terminal pro B-type natriuretic peptide in systematic screening for atrial fibrillation

Repeated Measurements of Cardiac Biomarkers in Atrial Fibrillation and Validation of the ABC Stroke Score Over Time

Hijazi, Ziad; Lindahl, Bertil; Oldgren, Jonas; Andersson, Ulrika et al.

Ingår i Journal of the American Heart Association, 2017

• DOI för Repeated Measurements of Cardiac Biomarkers in Atrial Fibrillation and Validation of the ABC Stroke Score Over Time

Risk of stroke in women and men with atrial fibrillation and only one additional CHA2DS2-VASC risk factor

Tomasdottir, Maria; Friberg, Leif; Hijazi, Ziad; Lindbäck, Johan et al.

Ingår i Journal of the American College of Cardiology, s. 327-327, 2017

• DOI för Risk of stroke in women and men with atrial fibrillation and only one additional CHA2DS2-VASC risk factor

Efficacy and Safety of Apixaban Compared With Warfarin in Patients With Atrial Fibrillation in Relation to Renal Function Over Time: Insights From the ARISTOTLE Randomized Clinical Trial

Hijazi, Ziad; Hohnloser, Stefan H; Andersson, Ulrika; Alexander, John H et al.

Ingår i JAMA cardiology, s. 451-460, 2016

• DOI för Efficacy and Safety of Apixaban Compared With Warfarin in Patients With Atrial Fibrillation in Relation to Renal Function Over Time: Insights From the ARISTOTLE Randomized Clinical Trial

Performance and Validation of a Novel Biomarker-Based Stroke Risk Score for Atrial Fibrillation

Oldgren, Jonas; Hijazi, Ziad; Lindbäck, Johan; Alexander, John H et al.

Ingår i Circulation, s. 1697-1707, 2016

• DOI för Performance and Validation of a Novel Biomarker-Based Stroke Risk Score for Atrial Fibrillation

NT-proBNP is a powerful predictor for incident atrial fibrillation: Validation of a multimarker approach

Svennberg, Emma; Lindahl, Bertil; Berglund, Lars; Eggers, Kai M. et al.

Ingår i International Journal of Cardiology, s. 74-81, 2016

• DOI för NT-proBNP is a powerful predictor for incident atrial fibrillation: Validation of a multimarker approach

Renal Function in Atrial Fibrillation A Multifaceted Dilemma

Hijazi, Ziad; Wallentin, Lars

Ingår i Circulation, s. 48-51, 2016

• DOI för Renal Function in Atrial Fibrillation A Multifaceted Dilemma

Cardiac biomarkers and left ventricular hypertrophy in relation to outcomes in patients with atrial fibrillation: experiences from the RELY trial

Hijazi, Ziad; Verdecchia, P.; Oldgren, Jonas; Andersson, Ulrika et al.

Ingår i EUROPEAN HEART JOURNAL, s. 47-47, 2016

External Validation Of The Biomarker-Based ABC-Bleeding Risk Score For Atrial Fibrillation

Hijazi, Ziad; Oldgren, Jonas; Lindbäck, Johan; Alexander, John et al.

Ingår i Journal of the American College of Cardiology, s. 893-893, 2016

External Validation Of The Biomarker-Based ABC-Stroke Risk Score For Atrial Fibrillation

Oldgren, Jonas; Hijazi, Ziad; Lindbäck, Johan; Alexander, John et al.

Ingår i Journal of the American College of Cardiology, s. 879-879, 2016

The 'obesity paradox' in atrial fibrillation: observations from the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) trial

Sandhu, Roopinder K.; Ezekowitz, Justin; Andersson, Ulrika; Alexander, John H. et al.

Ingår i European Heart Journal, s. 2869-2878, 2016

• DOI för The 'obesity paradox' in atrial fibrillation: observations from the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) trial

Apixaban 5 mg Twice Daily and Clinical Outcomes in Patients With Atrial Fibrillation and Advanced Age, Low Body Weight, or High Creatinine: A Secondary Analysis of a Randomized Clinical Trial

Alexander, John H; Andersson, Ulrika; Lopes, Renato D; Hijazi, Ziad et al.

Ingår i JAMA cardiology, s. 673-681, 2016

• DOI för Apixaban 5 mg Twice Daily and Clinical Outcomes in Patients With Atrial Fibrillation and Advanced Age, Low Body Weight, or High Creatinine: A Secondary Analysis of a Randomized Clinical Trial

Biomarkers of inflammation and risk of cardiovascular events in anticoagulated patients with atrial fibrillation

Hijazi, Ziad; Aulin, Julia; Andersson, Ulrika; Alexander, John H. et al.

Ingår i Heart, s. 508-517, 2016

• DOI för Biomarkers of inflammation and risk of cardiovascular events in anticoagulated patients with atrial fibrillation

The ABC risk score for patients with atrial fibrillation Reply

Hijazi, Ziad; Oldgren, Jonas; Lindbäck, Johan; Siegbahn, Agneta et al.

Ingår i The Lancet, s. 1980-1981, 2016

The ABC (age, biomarkers, clinical history) stroke risk score: a biomarker-based risk score for predicting stroke in atrial fibrillation

Hijazi, Ziad; Lindbäck, Johan; Alexander, John H.; Hanna, Michael et al.

Ingår i European Heart Journal, s. 1582-1590, 2016

• DOI för The ABC (age, biomarkers, clinical history) stroke risk score: a biomarker-based risk score for predicting stroke in atrial fibrillation

The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study

Hijazi, Ziad; Oldgren, Jonas; Lindbäck, Johan; Alexander, John H. et al.

Ingår i The Lancet, s. 2302-2311, 2016

• DOI för The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study

Efficacy and safety of apixaban compared with warfarin in relation to renal function over time in patients with atrial fibrillation: Insights from the ARISTOTLE trial

Hijazi, Ziad; Hohnloser, S. H.; Andersson, Ulrika; Alexander, J. H. et al.

Ingår i European Heart Journal, s. 339-339, 2015

Stroke and bleeding outcomes with apixaban versus warfarin in patients with high creatinine, low body weight or high age receiving standard dose apixaban for stroke prevention in atrial fibrillation

Alexander, J.; Andersson, Ulrika; Lopes, R. D.; Hijazi, Ziad et al.

Ingår i European Heart Journal, s. 345-345, 2015

External validation of the biomarker-based ABC-stroke risk score for atrial fibrillation

Hijazi, Ziad; Lindbäck, Johan; Östlund, Olof Petter; Siegbahn, Agneta et al.

Ingår i European Heart Journal, s. 710-711, 2015

Comparison of Cardiac Troponins I and T Measured with High-Sensitivity Methods for Evaluation of Prognosis in Atrial Fibrillation: An ARISTOTLE Substudy

Hijazi, Ziad; Siegbahn, Agneta; Andersson, Ulrika; Lindahl, Bertil et al.

Ingår i Clinical Chemistry, s. 368-378, 2015

• DOI för Comparison of Cardiac Troponins I and T Measured with High-Sensitivity Methods for Evaluation of Prognosis in Atrial Fibrillation: An ARISTOTLE Substudy

Reply: Anticoagulant-Related Nephropathy

Böhm, Michael; Ezekowitz, Michael D; Connolly, Stuart J; Eikelboom, John W et al.

Ingår i Journal of the American College of Cardiology, s. 2682, 2015

• DOI för Reply: Anticoagulant-Related Nephropathy

Changes in Renal Function in Patients With Atrial Fibrillation An Analysis From the RE-LY Trial

Boehm, Michael; Ezekowitz, Michael D.; Connolly, Stuart J.; Eikelboom, John W. et al.

Ingår i Journal of the American College of Cardiology, s. 2481-2493, 2015

• DOI för Changes in Renal Function in Patients With Atrial Fibrillation An Analysis From the RE-LY Trial

Interleukin-6 and C-reactive protein and risk for death and cardiovascular events in patients with atrial fibrillation

Aulin, Julia; Siegbahn, Agneta; Hijazi, Ziad; Ezekowitz, Michael D. et al.

Ingår i American Heart Journal, s. 1151-1160, 2015

• DOI för Interleukin-6 and C-reactive protein and risk for death and cardiovascular events in patients with atrial fibrillation

Growth Differentiation Factor 15, a Marker of Oxidative Stress and Inflammation, for Risk Assessment in Patients With Atrial Fibrillation: Insights From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial

Wallentin, Lars; Hijazi, Ziad; Andersson, Ulrika; Alexander, John H. et al.

Ingår i Circulation, s. 1847-1858, 2014

• DOI för Growth Differentiation Factor 15, a Marker of Oxidative Stress and Inflammation, for Risk Assessment in Patients With Atrial Fibrillation: Insights From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial

Interleukin-6 and C-reactive protein and risk for cardiovascular events and death in anticoagulated patients with atrial fibrillation

Aulin, Julia; Hijazi, Ziad; Andersson, Ulrika; Gersh, B. J. et al.

Ingår i European Heart Journal, s. 1115-1116, 2014

Galectin-3 is associated with worse clinical outcome in patients with atrial fibrillation: A substudy from the ARISTOTLE trial

Åsberg, S.; Hijazi, Ziad; Siegbahn, Agneta; Andersson, Ulrika et al.

Ingår i European Heart Journal, s. 426-426, 2014

A new biomarker based risk score for predicting major bleeding in atrial fibrillation - the ABC (age, biomarkers, current disease) risk score

Hijazi, Ziad; Lindbäck, Johan; Siegbahn, Agneta; Alexander, J. H. et al.

Ingår i European Heart Journal, s. 357-357, 2014

Response to Letter Regarding Article, "Efficacy and Safety of Dabigatran Compared With Warfarin in Relation to Baseline Renal Function in Patients With Atrial Fibrillation: A RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) Trial Analysis"

Hijazi, Ziad; Hohnloser, Stefan H.; Oldgren, Jonas; Andersson, Ulrika et al.

Ingår i Circulation, 2014

• DOI för Response to Letter Regarding Article, "Efficacy and Safety of Dabigatran Compared With Warfarin in Relation to Baseline Renal Function in Patients With Atrial Fibrillation: A RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) Trial Analysis"

High Sensitivity Troponin T and Risk Stratification in Patients with Atrial Fibrillation during Treatment with Apixaban or Warfarin

Hijazi, Ziad; Wallentin, Lars; Siegbahn, Agneta; Andersson, Ulrika et al.

Ingår i Journal of the American College of Cardiology, s. 52-61, 2014

• DOI för High Sensitivity Troponin T and Risk Stratification in Patients with Atrial Fibrillation during Treatment with Apixaban or Warfarin

Importance of Persistent Elevation of Cardiac Biomarkers in Atrial Fibrillation: a RE-LY Substudy

Hijazi, Ziad; Oldgren, Jonas; Andersson, Ulrika; Connolly, Stuart J. et al.

Ingår i Heart, s. 1193-1200, 2014

• DOI för Importance of Persistent Elevation of Cardiac Biomarkers in Atrial Fibrillation: a RE-LY Substudy

Antikoagulation vid akut stroke med förmaksflimmer Fem frågor bör besvaras innan behandlingen kan anses vara evidensbaserad: [Anticoagulation in acute stroke with atrial fibrillation. Five questions should be answered before the treatment can be considered evidence-based].

Terént, Andreas; Åsberg, Signild; Hijazi, Ziad

Ingår i Läkartidningen, s. 872-874, 2014

Efficacy and Safety of Dabigatran Compared With Warfarin in Relation to Baseline Renal Function in Patients With Atrial Fibrillation A RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) Trial Analysis

Hijazi, Ziad; Hohnloser, Stefan H.; Oldgren, Jonas; Andersson, Ulrika et al.

Ingår i Circulation, s. 961-970, 2014

• DOI för Efficacy and Safety of Dabigatran Compared With Warfarin in Relation to Baseline Renal Function in Patients With Atrial Fibrillation A RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) Trial Analysis

High-Sensitivity Troponin I for Risk Assessment in Patients With Atrial Fibrillation Insights From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial

Hijazi, Ziad; Siegbahn, Agneta; Andersson, Ulrika; Granger, Christopher B. et al.

Ingår i Circulation, s. 625-634, 2014

• DOI för High-Sensitivity Troponin I for Risk Assessment in Patients With Atrial Fibrillation Insights From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial

N-Terminal Pro-B-Type Natriuretic Peptide for Risk Assessment in Patients With Atrial Fibrillation: Insights from the ARISTOTLE trial

Hijazi, Ziad; Wallentin, Lars; Siegbahn, Agneta; Andersson, Ulrika et al.

Ingår i Journal of the American College of Cardiology, s. 2274-2284, 2013

• DOI för N-Terminal Pro-B-Type Natriuretic Peptide for Risk Assessment in Patients With Atrial Fibrillation: Insights from the ARISTOTLE trial

Biomarkers in atrial fibrillation: a clinical review

Hijazi, Ziad; Oldgren, Jonas; Siegbahn, Agneta; Granger, Christopher B et al.

Ingår i European Heart Journal, s. 1475-1480, 2013

• DOI för Biomarkers in atrial fibrillation: a clinical review

Reply: Higher N-Terminal Pro-B-Type Natriuretic Peptide May Be Related to Very Different Conditions

Hijazi, Ziad; Granger, Christopher B.; Wallentin, Lars

Ingår i Journal of the American College of Cardiology, s. 1635-1636, 2013

• DOI för Reply: Higher N-Terminal Pro-B-Type Natriuretic Peptide May Be Related to Very Different Conditions

Response to Letter Regarding Article, "Cardiac Biomarkers Are Associated With an Increased Risk of Stroke and Death in Patients With Atrial Fibrillation: A Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Substudy"

Hijazi, Ziad; Oldgren, Jonas; Wallentin, Lars; Andersson, Ulrika et al.

Ingår i Circulation, 2013

• DOI för Response to Letter Regarding Article, "Cardiac Biomarkers Are Associated With an Increased Risk of Stroke and Death in Patients With Atrial Fibrillation: A Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Substudy"

Combining High Sensitivity Troponin I and T Measurements Improves Prediction of Long-Term Clinical Outcomes in Patients With Atrial Fibrillation - An Aristotle Substudy

Hijazi, Ziad; Siegbahn, Agneta; Andersson, Ulrika; Granger, Christopher B. et al.

Ingår i Circulation, 2013

Cardiac Biomarkers Are Associated With an Increased Risk of Stroke and Death in Patients With Atrial Fibrillation: A Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Substudy

Hijazi, Ziad; Oldgren, Jonas; Andersson, Ulrika; Connolly, Stuart J. et al.

Ingår i Circulation, s. 1605-1616, 2012

• DOI för Cardiac Biomarkers Are Associated With an Increased Risk of Stroke and Death in Patients With Atrial Fibrillation: A Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Substudy

Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial

Hohnloser, Stefan H.; Hijazi, Ziad; Thomas, Laine; Alexander, John H. et al.

Ingår i European Heart Journal, s. 2821-2830, 2012

• DOI för Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial

Collaboration on the optimal timing of anticoagulation after ischaemic stroke and atrial fibrillation: a systematic review and prospective individual participant data meta-analysis of randomised controlled trials (CATALYST)

Dehbi, Hakim-Moulay; Fischer, Urs; Åsberg, Signild; Milling, Truman J. et al.

Ingår i The Lancet, s. 43-51, 2025

• DOI för Collaboration on the optimal timing of anticoagulation after ischaemic stroke and atrial fibrillation: a systematic review and prospective individual participant data meta-analysis of randomised controlled trials (CATALYST)
• Ladda ner fulltext (pdf) av Collaboration on the optimal timing of anticoagulation after ischaemic stroke and atrial fibrillation: a systematic review and prospective individual participant data meta-analysis of randomised controlled trials (CATALYST)

The Science of Prognosis in Psychiatry: A Review

Fusar-Poli, Paolo; Hijazi, Ziad; Stahl, Daniel; Steyerberg, Ewout W.

Ingår i JAMA psychiatry, s. 1289-1297, 2018

• DOI för The Science of Prognosis in Psychiatry: A Review

Application of Biomarkers for Risk Stratification in Patients with Atrial Fibrillation

Hijazi, Ziad; Oldgren, Jonas; Siegbahn, Agneta; Wallentin, Lars

Ingår i Clinical Chemistry, s. 152-164, 2017

• DOI för Application of Biomarkers for Risk Stratification in Patients with Atrial Fibrillation

Stora studier av NOAK visar på gott och säkert strokeskydd

Hijazi, Ziad; Oldgren, Jonas

Ingår i Läkartidningen, 2015

New Risk Markers in Atrial Fibrillation

Hijazi, Ziad

2013

• Ladda ner fulltext (pdf) av New Risk Markers in Atrial Fibrillation

Growth differentiation factor 15 is an independent marker of risk of major bleeding in atrial fibrillation: insights from the RE-LY trial

Hijazi, Ziad; Oldgren, Jonas; Andersson, Ulrika; Connolly, S. J. et al.

s. 429-429, 2016

Screening of plasma biomarkers for heart failure hospitalizations and heart failure subtype in patients with atrial fibrillation

Pol, Tymon; Lindbäck, Johan; Oldgren, Jonas; Alexander, John H. et al.